{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T23:38:27Z","timestamp":1782949107254,"version":"3.54.5"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T00:00:00Z","timestamp":1649721600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T00:00:00Z","timestamp":1649721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["IMI2-FPP116074-2"],"award-info":[{"award-number":["IMI2-FPP116074-2"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012514","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red-Fisiopatolog\u00eda de la Obesidad y Nutrici\u00f3n","doi-asserted-by":"publisher","award":["PI16\/01402"],"award-info":[{"award-number":["PI16\/01402"]}],"id":[{"id":"10.13039\/501100012514","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The objective is to assess the impact of anticoagulant treatment in non-valvular atrial fibrillation (AF) and different categories of renal dysfunction in real world. Electronic Health recordings of patients with diagnosis of AF and renal function collected throughout 5\u00a0years and classified according to KDIGO categories. Stroke, transitory ischemic attack (TIA), intracranial hemorrhage and all-cause mortality were identified. Anticoagulant treatments during the study period were classified in untreated (never received therapy), VKA, NOAC and Aspirin. The risk of events was calculated by Cox-proportional hazard models adjusted by confounders. A total of 65,734 patients with AF, mean age 73.3\u2009\u00b1\u200910.49\u00a0years old and 47% females and follow-up of 3.2\u00a0years were included. KDIGO classification were: G1 33,903 (51.6%), G2 17,456 (26.6%), G3 8024 (12.2%) and G4 6351 (9.7%). There were 8592 cases of stroke and TIA, 437 intracranial hemorrhage, and 9603 all-cause deaths (incidence 36, 2 and 38 per 10<jats:sup>3<\/jats:sup> person\/year, respectively). 4.1% of patients with CHA2DS2-VASc Score 2 or higher did not receive anticoagulant therapy. Risk of stroke, TIA, and all-cause mortality increased from G1 to G4 groups. Anticoagulant treatments reduced the risk of events in the four categories, but NOAC seemed to offer significantly better protection. Renal dysfunction increases the risk of events in AF and anticoagulant treatments reduced the risk of stroke and all-cause mortality, although NOAC were better than VKA. Efforts should be done to reduce the variability in the use of anticoagulants even in this high risk group.<\/jats:p>","DOI":"10.1038\/s41598-022-10164-5","type":"journal-article","created":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T13:03:13Z","timestamp":1649768593000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Real world data of anticoagulant treatment in non-valvular atrial fibrillation across renal function status"],"prefix":"10.1038","volume":"12","author":[{"given":"Jose Miguel","family":"Calderon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Sauri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Uso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Luis","family":"Trillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Redon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jose","family":"Forner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,12]]},"reference":[{"key":"10164_CR1","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1056\/NEJMcp2023658","volume":"384","author":"GF Michaud","year":"2021","unstructured":"Michaud, G. F. & Stevenson, W. G. Atrial Fibrillation. N Engl J Med. 384, 353\u2013361 (2021).","journal-title":"N Engl J Med."},{"key":"10164_CR2","doi-asserted-by":"publisher","first-page":"3958","DOI":"10.1093\/eurheartj\/ehy622","volume":"39","author":"RM John","year":"2018","unstructured":"John, R. M., Michaud, G. F. & Stevenson, W. G. Atrial fibrillation hospitalization, mortality, and therapy. Eur Heart J. 39, 3958\u20133960 (2018).","journal-title":"Eur Heart J."},{"key":"10164_CR3","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jacc.2019.01.011","volume":"74","author":"CT January","year":"2019","unstructured":"January, C. T. et al. 2019 AHA\/ACC\/HRS Focused Update of the 2014 AHA\/ACC\/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 74, 104\u2013132 (2019).","journal-title":"J Am Coll Cardiol."},{"issue":"Suppl O","key":"10164_CR4","doi-asserted-by":"publisher","first-page":"O53","DOI":"10.1093\/eurheartj\/suaa180","volume":"22","author":"TF Chao","year":"2020","unstructured":"Chao, T. F., Nedeljkovic, M. A., Lip, G. Y. H. & Potpara, T. S. Stroke prevention in atrial fibrillation: comparison of recent international guidelines. Eur Heart J Suppl. 22(Suppl O), O53\u2013O60 (2020).","journal-title":"Eur Heart J Suppl."},{"issue":"42","key":"10164_CR5","first-page":"373","volume":"2020","author":"Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom- Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE, Fauchier L, Filippatos G, Kalman JM, La Meir M, Lane DA, Lebeau JP, Lettino M, Lip GYH, Pinto FJ, Thomas GN, Valgimigli M, Van Gelder IC, Van Putte BP, Watkins CL; ESC Scientific Document Group","year":"2020","unstructured":"Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom- Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE, Fauchier L, Filippatos G, Kalman JM, La Meir M, Lane DA, Lebeau JP, Lettino M, Lip GYH, Pinto FJ, Thomas GN, Valgimigli M, Van Gelder IC, Van Putte BP, Watkins CL; ESC Scientific Document Group. ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio- Thoracic Surgery (EACTS). Eur Heart J 2020(42), 373\u2013498 (2020).","journal-title":"Eur Heart J"},{"key":"10164_CR6","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1093\/eurheartj\/ehs435","volume":"34","author":"GY Lip","year":"2013","unstructured":"Lip, G. Y. Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why?. Eur Heart J. 34, 1041\u20131049 (2013).","journal-title":"Eur Heart J."},{"issue":"11","key":"10164_CR7","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/j.jacc.2021.01.028","volume":"77","author":"AC Lai","year":"2021","unstructured":"Lai, A. C. et al. A Personalized Approach to Chronic Kidney Disease and Cardiovascular Disease: JACC Review Topic of the Week. J Am Coll Cardiol. 77(11), 1470\u20131479 (2021).","journal-title":"J Am Coll Cardiol."},{"key":"10164_CR8","unstructured":"Shen NN, Wu Y, Wang N, Kong LC, Zhang C, Wang JL, Gu ZC, Chen J. Direct Oral"},{"key":"10164_CR9","doi-asserted-by":"crossref","unstructured":"Anticoagulants vs. Vitamin-K Antagonists in the Elderly With Atrial Fibrillation: A Systematic Review Comparing Benefits and Harms Between Observational Studies and Randomized Controlled Trials. Front Cardiovasc Med. 2020;7:132.","DOI":"10.3389\/fcvm.2020.00132"},{"key":"10164_CR10","doi-asserted-by":"crossref","unstructured":"Bang OY, On YK, Lee MY, Jang SW, Han S, Han S, Won MM, Park YJ, Lee JM, Choi HY, Kang S, Suh HS, Kim YH. The risk of stroke\/systemic embolism and major bleeding in Asian patients with non-valvular atrial fibrillation treated with non-vitamin K oral anticoagulants compared to warfarin: Results from a real-world data analysis. PLoS One. 2020;15:e0242922.","DOI":"10.1371\/journal.pone.0242922"},{"key":"10164_CR11","doi-asserted-by":"publisher","first-page":"I1","DOI":"10.1093\/eurheartj\/suaa100","volume":"22","author":"M Domek","year":"2020","unstructured":"Domek, M., Gumprecht, J., Ding, W. Y., Lip, G. Y. H. & Lane, D. A. Practice-derived data on non-vitamin K antagonist oral anticoagulant therapy to complement observations from randomized trials. Eur Heart J Suppl. 22, I1\u2013I12 (2020).","journal-title":"Eur Heart J Suppl."},{"key":"10164_CR12","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.3390\/jcm9051398","volume":"9","author":"L Anghel","year":"2020","unstructured":"Anghel, L., Sasc\u0103u, R., Trifan, A., Zota, I. M. & St\u0103tescu, C. Non-Vitamin K Antagonist Oral Anticoagulants and the Gastrointestinal Bleeding Risk in Real-World Studies. J Clin Med. 9, 1398 (2020).","journal-title":"J Clin Med."},{"key":"10164_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-020-07110-w","author":"X Sun","year":"2020","unstructured":"Sun, X. et al. Hemorrhage Risk Profiles among Different Antithrombotic Regimens: Evidence from a Real-World Analysis of Postmarketing Surveillance Data. Cardiovasc Drugs Ther. https:\/\/doi.org\/10.1007\/s10557-020-07110-w (2020).","journal-title":"Cardiovasc Drugs Ther."},{"key":"10164_CR14","doi-asserted-by":"crossref","unstructured":"Ozaki AF, Choi AS, Le QT, Ko DT, Han JK, Park SS, Jackevicius CA. Real-World Adherence and Persistence to Direct Oral Anticoagulants in Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis. Circ Cardiovasc Qual Outcomes. 2020;13:e005969.","DOI":"10.1161\/CIRCOUTCOMES.119.005969"},{"key":"10164_CR15","doi-asserted-by":"publisher","first-page":"107602961989876","DOI":"10.1177\/1076029619898764","volume":"26","author":"NR Hill","year":"2020","unstructured":"Hill, N. R. et al. A Systematic Review of Network Meta-Analyses and Real-World Evidence Comparing Apixaban and Rivaroxaban in Nonvalvular Atrial Fibrillation. Clin Appl Thromb Hemost. 26, 1076029619898764 (2020).","journal-title":"Clin Appl Thromb Hemost."},{"key":"10164_CR16","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1080\/03007995.2019.1647020","volume":"35","author":"JB Briere","year":"2019","unstructured":"Briere, J. B. et al. Impact of methodological choices on a meta-analysis of real-world evidence comparing non-vitamin-K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation. Curr Med Res Opin. 35, 1867\u20131872 (2019).","journal-title":"Curr Med Res Opin."},{"key":"10164_CR17","doi-asserted-by":"publisher","first-page":"1574541","DOI":"10.1080\/20016689.2019.1574541","volume":"7","author":"CI Coleman","year":"2019","unstructured":"Coleman, C. I. et al. Meta-analysis of real-world evidence comparing non-vitamin K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation. J Mark Access Health Policy. 7, 1574541. https:\/\/doi.org\/10.1080\/20016689.2019.1574541 (2019).","journal-title":"J Mark Access Health Policy."},{"key":"10164_CR18","doi-asserted-by":"crossref","unstructured":"Bowrin K, Briere JB, Fauchier L, Coleman C, Millier A, Toumi M, Clay E, Levy P. Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France. PLoS One. 2020;15:e0225301.","DOI":"10.1371\/journal.pone.0225301"},{"key":"10164_CR19","doi-asserted-by":"publisher","unstructured":"Ashton V, Kerolus-Georgi S, Moore KT. The Pharmacology, Efficacy, and Safety of Rivaroxaban in Renally Impaired Patient Populations. J Clin Pharmacol. 2021: doi: https:\/\/doi.org\/10.1002\/jcph.1838.","DOI":"10.1002\/jcph.1838"},{"key":"10164_CR20","unstructured":"The EU General Data Protection Regulation GDPR. https:\/\/gdpr-info.eu\/"},{"key":"10164_CR21","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s12325-020-01568-8","volume":"38","author":"M Murton","year":"2021","unstructured":"Murton, M. et al. Burden of Chronic Kidney Disease by KDIGO Categories of Glomerular Filtration Rate and Albuminuria: A Systematic Review. Adv Ther. 38, 180\u2013200 (2021).","journal-title":"Adv Ther."},{"key":"10164_CR22","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1002\/ehf2.12595","volume":"7","author":"JL Holgado","year":"2020","unstructured":"Holgado, J. L. et al. Acute kidney injury in heart failure: a population study. ESC Heart Fail. 7, 415\u2013422 (2020).","journal-title":"ESC Heart Fail."},{"key":"10164_CR23","doi-asserted-by":"crossref","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150:604\u2013612.","DOI":"10.7326\/0003-4819-150-9-200905050-00006"},{"key":"10164_CR24","unstructured":"ATC\/DDD Index. WHO Collaborating Centre for Drug Statistics Methodology, ATC classification index with DDDs, 2021. Oslo, Norway 2020."},{"key":"10164_CR25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11886-021-01456-9","volume":"23","author":"EM White","year":"2021","unstructured":"White, E. M. & Coons, J. C. Direct Oral Anticoagulant Use in Special Populations: Elderly, Obesity, and Renal Failure. Curr Cardiol Rep. 23, 27. https:\/\/doi.org\/10.1007\/s11886-021-01456-9 (2021).","journal-title":"Curr Cardiol Rep."},{"key":"10164_CR26","doi-asserted-by":"publisher","unstructured":"Lau WL. Controversies: Stroke Prevention in Chronic Kidney Disease. J Stroke Cerebrovasc Dis. 2021:105679. doi: https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.","DOI":"10.1016\/j.jstrokecerebrovasdis"},{"key":"10164_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-021-07144-8","author":"C Chen","year":"2021","unstructured":"Chen, C. et al. Effect of Rivaroxaban or Apixaban in Atrial Fibrillation Patients with Stage 4\u20135 Chronic Kidney Disease or on Dialysis. Cardiovasc Drugs Ther. https:\/\/doi.org\/10.1007\/s10557-021-07144-8 (2021).","journal-title":"Cardiovasc Drugs Ther."},{"key":"10164_CR28","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ccep.2020.11.001","volume":"13","author":"M Stefil","year":"2021","unstructured":"Stefil, M., Nabrdalik, K. & Lip, G. Y. H. Renal Disease and Atrial Fibrillation. Card Electrophysiol Clin. 13, 95\u2013112 (2021).","journal-title":"Card Electrophysiol Clin."},{"key":"10164_CR29","doi-asserted-by":"publisher","unstructured":"Proietti M, Vitolo M, Lip GYH. Integrated care and outcomes in patients with atrial fibrillation and comorbidities. Eur J Clin Invest. 2021:e13498. doi: https:\/\/doi.org\/10.1111\/eci.13498.","DOI":"10.1111\/eci.13498"},{"issue":"20","key":"10164_CR30","doi-asserted-by":"publisher","first-page":"31203","DOI":"10.1053\/j.ajkd.2020.12.004","volume":"S0272\u20136386","author":"JB Wetmore","year":"2021","unstructured":"Wetmore, J. B. et al. CKD Progression in Medicare Beneficiaries With Nonvalvular Atrial Fibrillation Treated With Apixaban Versus Warfarin. Am J Kidney Dis. S0272\u20136386(20), 31203\u201331208. https:\/\/doi.org\/10.1053\/j.ajkd.2020.12.004 (2021).","journal-title":"Am J Kidney Dis."},{"key":"10164_CR31","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3390\/jcm10010083","volume":"10","author":"M Magnocavallo","year":"2020","unstructured":"Magnocavallo, M. et al. Thromboembolic and Bleeding Risk in Atrial Fibrillation Patients with Chronic Kidney Disease: Role of Anticoagulation Therapy. J Clin Med. 10, 83. https:\/\/doi.org\/10.3390\/jcm10010083 (2020).","journal-title":"J Clin Med."},{"key":"10164_CR32","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1016\/j.jacep.2020.06.036","volume":"6","author":"MA Agarwal","year":"2020","unstructured":"Agarwal, M. A. et al. Clinical Outcomes of Warfarin Initiation in Advanced Chronic Kidney Disease Patients With Incident Atrial Fibrillation. JACC Clin Electrophysiol. 6, 1658\u20131668 (2020).","journal-title":"JACC Clin Electrophysiol."},{"key":"10164_CR33","doi-asserted-by":"publisher","unstructured":"Bansal N, Zelnick LR, Soliman EZ, Anderson A, Christenson R, DeFilippi C, Deo R, Feldman HI, He J, Ky B, Kusek J, Lash J, Seliger S, Shafi T, Wolf M, Go AS, Shlipak MG; CRIC Study Investigators. Change in Cardiac Biomarkers and Risk of Incident Heart Failure and Atrial Fibrillation in CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis. 2020:S0272\u20136386(20)31137\u20139. doi: https:\/\/doi.org\/10.1053\/j.ajkd.2020.09.021.","DOI":"10.1053\/j.ajkd.2020.09.021"},{"key":"10164_CR34","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1097\/FJC.0000000000000911","volume":"76","author":"Z Heleniak","year":"2020","unstructured":"Heleniak, Z., Papuga-Szela, E., Krzysztof, P. & Anetta, U. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Chronic Kidney Disease Stage G4: A Single-Center Experience. J Cardiovasc Pharmacol. 76, 671\u2013677 (2020).","journal-title":"J Cardiovasc Pharmacol."},{"key":"10164_CR35","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1378\/chest.15-1719","volume":"149","author":"K Dahal","year":"2016","unstructured":"Dahal, K., Kunwar, S., Rijal, J., Schulman, P. & Lee, J. Stroke, Major Bleeding, and Mortality Outcomes in Warfarin Users With Atrial Fibrillation and Chronic Kidney Disease: A Meta-Analysis of Observational Studies. Chest 149, 951\u2013959 (2016).","journal-title":"Chest"},{"key":"10164_CR36","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.amjcard.2020.07.004","volume":"132","author":"WY Ding","year":"2020","unstructured":"Ding, W. Y., Lip, G. Y. H., Pastori, D. & Shantsila, A. Effects of Atrial Fibrillation and Chronic Kidney Disease on Major Adverse Cardiovascular Events. Am J Cardiol. 132, 72\u201378 (2020).","journal-title":"Am J Cardiol."},{"key":"10164_CR37","doi-asserted-by":"publisher","unstructured":"Ding WY, Rivera-Caravaca JM, Shantsila A, Marin F, Gupta D, Rold\u00e1n V, Lip GYH. Outcomes in VKA-treated patients with atrial fibrillation and chronic kidney disease: Clinical trials vs 'real-world'. Int J Clin Pract. 2020:e13888. doi: https:\/\/doi.org\/10.1111\/ijcp.13888.","DOI":"10.1111\/ijcp.13888"},{"key":"10164_CR38","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1378\/chest.13-2103","volume":"145","author":"A Banerjee","year":"2014","unstructured":"Banerjee, A. et al. A prospective study of estimated glomerular filtration rate and outcomes in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. Chest 145, 1370\u20131382 (2014).","journal-title":"Chest"},{"key":"10164_CR39","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1016\/j.jacc.2014.09.051","volume":"64","author":"AN Bonde","year":"2014","unstructured":"Bonde, A. N. et al. Net Clinical Benefit of Antithrombotic Therapy in Patients With Atrial Fibrillation and Chronic Kidney Disease: A Nationwide Observational Cohort Study. J Am Coll Cardiol 64, 2471\u20132482 (2014).","journal-title":"J Am Coll Cardiol"},{"key":"10164_CR40","doi-asserted-by":"crossref","unstructured":"Randhawa MS, Vishwanath R, Rai MP, Wang L, Randhawa AK, Abela G, Dhar G. Association Between Use of Warfarin for Atrial Fibrillation and Outcomes Among Patients With End-Stage Renal Disease: A Systematic Review and Meta-analysis. JAMA Netw Open. 2020;3:e202175.","DOI":"10.1001\/jamanetworkopen.2020.2175"},{"key":"10164_CR41","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1681\/ASN.2008080824","volume":"20","author":"KE Chan","year":"2009","unstructured":"Chan, K. E., Lazarus, J. M., Thadhani, R. & Hakim, R. M. Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients. J Am Soc Nephrol. 20, 872\u2013881 (2009).","journal-title":"J Am Soc Nephrol."},{"key":"10164_CR42","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ahj.2016.09.016","volume":"184","author":"H Van Der Meersch","year":"2017","unstructured":"Van Der Meersch, H., De Bacquer, D. & De Vriese, A. S. Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation: a systematic review and meta-analysis. Am Heart J. 184, 37\u201346 (2017).","journal-title":"Am Heart J."},{"key":"10164_CR43","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.thromres.2020.11.036","volume":"198","author":"M Alhousani","year":"2021","unstructured":"Alhousani, M. et al. Using oral anticoagulants among chronic kidney disease patients to prevent recurrent venous thromboembolism: A systematic review and meta-analysis. Thromb Res. 198, 103\u2013114 (2021).","journal-title":"Thromb Res."},{"key":"10164_CR44","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1093\/ckj\/sfy133","volume":"12","author":"KB De Aquino Moura","year":"2019","unstructured":"De Aquino Moura, K. B. et al. Anticoagulant-related nephropathy: systematic review and meta-analysis. Clin Kidney J. 12, 400\u2013407 (2019).","journal-title":"Clin Kidney J."},{"key":"10164_CR45","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.chest.2018.07.040","volume":"154","author":"GYH Lip","year":"2018","unstructured":"Lip, G. Y. H. et al. Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report. Chest 154, 1121\u20131201 (2018).","journal-title":"Chest"},{"key":"10164_CR46","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1080\/13696998.2020.1792917","volume":"23","author":"K Bowrin","year":"2020","unstructured":"Bowrin, K., Briere, J. B., Levy, P., Toumi, M. & Millier, A. Use of real-world evidence in meta-analyses and cost-effectiveness models. J Med Econ. 23, 1053\u20131060 (2020).","journal-title":"J Med Econ."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10164-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10164-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10164-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T01:51:53Z","timestamp":1669341113000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10164-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,12]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["10164"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-10164-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,12]]},"assertion":[{"value":"11 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6123"}}